Efferon's Pediatric Sepsis Device Lands CE Mark and $2M Revenue Path

Efferon NEO, the first CE-marked multimodal blood purification device for pediatric sepsis, is used in ICUs across 30 countries and targets $2M annualized revenue by end of 2026.